Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Trevi Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Trevi Therapeutics, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206390
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $9,941 | $7,811 |
| General and administrative | 4,971 | 3,659 |
| Total operating expenses | 14,912 | 11,470 |
| Loss from operations | (14,912) | (11,470) |
| Other income (expense): | ||
| Interest income, net | 1,696 | 1,125 |
| Other income (expense), net | 4 | (6) |
Item 1. Condensed Consolidated Financial Statements.
FAQ
- What is Trevi Therapeutics, Inc.'s G&A?
- Trevi Therapeutics, Inc. (TRVI) reported G&A of $4.97M in Q1 2026.
- How has Trevi Therapeutics, Inc.'s G&A changed year-over-year?
- Trevi Therapeutics, Inc.'s G&A increased by 35.9% year-over-year, from $3.66M to $4.97M.
- What is the long-term trend for Trevi Therapeutics, Inc.'s G&A?
- Over 4 years (2021 to 2025), Trevi Therapeutics, Inc.'s G&A has grown at a 13.7% compound annual growth rate (CAGR), from $9.49M to $15.85M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Trevi Therapeutics, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude